Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $11.48, but opened at $11.96. Bavarian Nordic shares last traded at $11.96, with a volume of 408 shares traded.
Bavarian Nordic Stock Performance
The firm has a fifty day moving average price of $10.53 and a 200 day moving average price of $9.95. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of 12.08 and a beta of 1.25.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%. The firm had revenue of $316.47 million for the quarter.
About Bavarian Nordic
Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.
Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.
Read More
- Five stocks we like better than Bavarian Nordic
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
- Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
